PolyProx
Cambridge
About PolyProx
PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.7M
- Funding stage: Seed
- Last round: Seed (Mar 2020)
- Website: polyprox.com
- Phone: +44 (0)1223 804 420
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/polyprox-2241778 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.